Abstract
Therapeutic myocardial angiogenesis and arteriogenesis represent a novel treatment strategy for patients with angina refractory to traditional medical and surgical therapies. The fibroblast growth factors are a family of proteins that are known mediators of angio-/arteriogenesis. Based on promising preclinical animal data, a series of four randomized placebo-controlled clinical trials have been conducted to determine the safety and efficacy of local delivery of fibroblast growth factor 4 with the use of adenovirus-vector-mediated gene transfer to induce myocardial angio-/arteriogenesis in patients with stable angina. This review describes the scientific rationale underlying these clinical trials, provides an overview of their results, and discusses the implications for future studies.
Original language | English (US) |
---|---|
Pages (from-to) | 133-141 |
Number of pages | 9 |
Journal | Trends in Cardiovascular Medicine |
Volume | 18 |
Issue number | 4 |
DOIs | |
State | Published - May 2008 |
Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine